8-K: Globus Medical Completes Acquisition of Nevro Corp. for $5.85 Per Share

Nevro Corp. is now a wholly-owned subsidiary of Globus Medical after the completion of a merger on April 3, 2025, with Nevro shareholders receiving $5.85 per share.

Summary

• Nevro Corp. has completed its merger with Palmer Merger Sub, Inc., a subsidiary of Globus Medical, on April 3, 2025.
• As a result, Nevro is now a wholly-owned subsidiary of Globus Medical.
• Nevro shareholders received $5.85 in cash for each share of Nevro common stock they held.
• Outstanding Nevro stock options were cancelled without consideration.
• Nevro restricted stock units (RSUs) were converted into the right to receive cash based on the merger consideration.
• Performance-based RSUs (PSUs) were converted into the right to receive cash based on target or actual performance, whichever was greater, multiplied by the merger consideration.
• A warrant held by Braidwell Transaction Holdings LLC Series 4 was converted into the right to receive cash equal to the Black-Scholes value of the warrant.
• Nevro terminated and prepaid its Credit Agreement, paying approximately $227.1 million, which included principal, interest, fees, and expenses.
• Nevro's shares have been delisted from the New York Stock Exchange (NYSE).
• All Nevro directors resigned, and directors of Merger Sub became the directors of Nevro.
• The officers of Merger Sub became the officers of Nevro.
• Nevro's certificate of incorporation and bylaws were amended and restated.
• Nevro repaid approximately $190 million in aggregate principal amount outstanding, together with approximately $2.61 million in accrued interest on its 2.75% Convertible Senior Notes due 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The completion of the merger is a positive outcome for shareholders who received cash for their shares. The repayment of debt is also a positive development. However, the delisting of shares and departure of directors are neutral to slightly negative.

Positives

• Shareholders received $5.85 per share in cash.
• Nevro's debt under the Credit Agreement was fully repaid.
• The merger provides Nevro with the resources and stability of being part of a larger organization, Globus Medical.

Negatives

• Nevro stock options were cancelled without consideration.
• Nevro shares are no longer publicly traded on the NYSE.
• Former Nevro directors and officers have departed from their positions.

Risks

• The integration of Nevro into Globus Medical may present challenges.
• There may be unforeseen costs or liabilities associated with the merger.
• The loss of key personnel from Nevro could impact the business.

Future Outlook

The document does not contain specific forward-looking statements regarding the combined entity's future performance, but it implies that Nevro will operate as a subsidiary of Globus Medical.

Industry Context

This acquisition reflects a trend of consolidation in the medical device industry, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach. Globus Medical's acquisition of Nevro allows it to enter or strengthen its position in the neuromodulation market.

Comparison to Industry Standards

• Globus Medical's acquisition of Nevro is similar to other acquisitions in the medical device industry, such as Medtronic's acquisition of Mazor Robotics, which allowed Medtronic to expand its presence in the surgical robotics market.
• The $5.85 per share price represents a premium paid by Globus Medical to acquire Nevro, which is typical in acquisition scenarios.
• The delisting of Nevro's shares from the NYSE is a standard procedure following an acquisition where the company becomes a wholly-owned subsidiary.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders received cash for their shares.
• Employees may experience changes as a result of the integration with Globus Medical.
• Customers may see changes in product offerings or service as a result of the merger.

Next Steps

• Globus Medical will integrate Nevro into its operations.
• Nevro will operate as a wholly-owned subsidiary of Globus Medical.
• Nevro will file a Certification and Notice of Termination of Registration on Form 15 with the SEC to suspend its reporting obligations.

Key Dates

Keywords

merger, acquisition, Nevro, Globus Medical, delisting, shareholders, stock options, RSUs, PSUs, Credit Agreement, NYSE